Publikationen

British Journal of Haematology: (2017-07-05)

Dang N.H.; Ogura M.; Castaigne S.; Fayad L.E.; Jerkeman M.; Radford J.; Pezzutto A.; Bondarenko I.; Stewart D.A.; Shnaidman M.; Sullivan S.; Vandendries E.; Tobinai K.; Ramchandren R.; Hamlin P.A.; Giné E.; Ando K.

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Keywords: Inotuzumab Ozogamicin, B-Cell Non-Hodgkin Lymphoma, CD22+, Antibody-Drug Conjugate, Rituximab

Type: Letter

PubMed: 28677896
Official URL: https://doi.org/10.1111/bjh.14820
MDC Repository: https://edoc.mdc-berlin.de/16648/